# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-090782
Filing Date
2024-08-05
Accepted
2024-08-05 16:18:22
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | spro-20240630.htm iXBRL | 10-Q | 2097475
2 | EX-31.1 | spro-ex31_1.htm | EX-31.1 | 10585
3 | EX-31.2 | spro-ex31_2.htm | EX-31.2 | 10732
4 | EX-32 | spro-ex32.htm | EX-32 | 8481
| Complete submission text file | 0000950170-24-090782.txt |  | 7659920

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | spro-20240630.xsd | EX-101.SCH | 1312399
59 | EXTRACTED XBRL INSTANCE DOCUMENT | spro-20240630_htm.xml | XML | 1019869

Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 241175011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)